Projects per year
Abstract
Biotin protein ligase (BPL) represents a promising target for the discovery of new antibacterial chemotherapeutics. Here we review the central role of BPL for the survival and virulence of clinically important Staphylococcus aureus in support of this claim. X-ray crystallography structures of BPLs in complex with ligands and small molecule inhibitors provide new insights into the mechanism of protein biotinylation, and a template for structure guided approaches to the design of inhibitors for antibacterial discovery. Most BPLs employ an ordered ligand binding mechanism for the synthesis of the reaction intermediate biotinyl-5 -AMP from substrates biotin and ATP. Recent studies reporting chemical analogs of biotin and biotinyl-5 -AMP as BPL inhibitors that represent new classes of anti-S. aureus agents are reviewed. We highlight strategies to selectively inhibit bacterial BPL over the mammalian equivalent using a 1,2,3-triazole isostere to replace the labile phosphoanhydride naturally present in biotinyl-5 -AMP. A novel in situ approach to improve the detection of triazole-based inhibitors is also presented that could potentially be widely applied to other protein targets.
Original language | English |
---|---|
Pages (from-to) | 4 - 20 |
Number of pages | 17 |
Journal | Current Topics in Medicinal Chemistry |
Volume | 14 |
Issue number | 1 |
DOIs | |
Publication status | Published - 2014 |
Projects
- 1 Finished
-
Inhibitors of biotin protein ligase: a new class of antibiotic targetting Staphylcoccus aureus
Wilce, M. (Primary Chief Investigator (PCI)), Abell, A. (Partner Investigator (PI)) & Turnidge, J. D. (Partner Investigator (PI))
NHMRC - National Health and Medical Research Council (Australia)
1/01/11 → 3/11/13
Project: Research